Brooke M Mcmahan, AUD, CNIM | |
15405 Daybright Dr, Edmond, OK 73013-9627 | |
(405) 249-1379 | |
Not Available |
Full Name | Brooke M Mcmahan |
---|---|
Gender | Female |
Speciality | Specialist/technologist, Other - Eeg |
Location | 15405 Daybright Dr, Edmond, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538329206 | NPI | - | NPPES |
200197630A | Medicaid | OK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 359 (Oklahoma) | Secondary |
246ZE0500X | Specialist/technologist, Other - Eeg | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Brooke M Mcmahan, AUD, CNIM 15405 Daybright Dr, Edmond, OK 73013-9627 Ph: (405) 249-1379 | Brooke M Mcmahan, AUD, CNIM 15405 Daybright Dr, Edmond, OK 73013-9627 Ph: (405) 249-1379 |
News Archive
Gentium S.p.A. today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.
Intensive parenting and health education provided in homes of pregnant American Indian teens reduced the mothers' illegal drug use, depression and behavior problems, and set their young children on track to meet behavioral and emotional milestones they may have otherwise missed.
The texture of breast cancer tissue differs from that of healthy tissue. Using a cutting-edge tissue diagnostic device, a group of researchers in Basel, Switzerland, has determined one key difference: cancerous tissue is a mix of stiff and soft zones, whereas healthy tissue has uniform stiffness.
Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activities and Vygon, a French family-run business that develops, produces and markets medical devices, including catheters and implantable ports for administering chemotherapy treatments, today announce their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.
› Verified 5 days ago